PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance

Autor: Tao Zhang, Qin Liu, Yingfan Zhu, Songfa Zhang, Qiaohua Peng, Amanda Louise Strickland, Wenxin Zheng, Feng Zhou
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Cancer Management and Research
ISSN: 1179-1322
8999-1702
Popis: Tao Zhang,1,* Qin Liu,2,* Yingfan Zhu,1 Songfa Zhang,3 Qiaohua Peng,3 Amanda Louise Strickland,4 Wenxin Zheng,4,5 Feng Zhou2 1Department of Gynecology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Pathology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 4Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; 5Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA*These authors contributed equally to this workCorrespondence: Feng ZhouDepartment of Pathology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou City, Zhejiang Province, 310006, People’s Republic of ChinaTel +86-571-89991702Fax +86-571-87061878Email fungchew@zju.edu.cnPurpose: Programmed death-ligand 1 (PD-L1) has been widely used as a prognostic biomarker and an immunotherapeutic target in numerous cancers, but information on the clinical significance of its expression in endometrial serous carcinoma (ESC) is largely lacking. Here, we evaluate the predictive value of PD-L1 expression in ESC.Materials and Methods: A total of 79 cases of ESC accessioned between January 2003 and September 2015 were selected for further analysis. PD-L1 expression was evaluated in whole tissue sections of these cases by using the tumor proportion score (TPS, cut-off 1%) and combined positive score (CPS, cut-off 1) scoring methods.Results: Overall, there was a heterogeneous expression of PD-L1, focal or patchy, in ESCs. PD-L1 positivity was observed in 43.0% of ESCs by TPS and 73.4% of ESCs by CPS. Kaplan–Meier survival analysis showed that patients with PD-L1-positive tumors suffered significantly worse OS and PFS, when compared with PD-L1 negative tumors (log-rank p = 0.037 and p = 0.003, respectively). In contrast, PD-L1 positivity by CPS within the ESC cases showed no statistical significance for OS and PFS (log-rank p = 0.720 and p = 0.928, respectively). Multivariate Cox analysis showed that PD-L1 positivity by TPS was significantly associated with PFS (HR = 1.921, p = 0.039) but not OS (HR = 1.229, p = 0.631).Conclusion: PD-L1 expression is frequently found in ESC, suggesting a potential role of the PD-1/PD-L1 pathway as a potential therapeutic target for these tumors. PD-L1 expression by TPS also serves as a negative prognostic marker in ESC and implies an unfavorable outcome.Keywords: PD-L1, endometrial serous carcinoma, endometrial cancer, immune therapy
Databáze: OpenAIRE
Externí odkaz: